n3 PUFA and Muscle-disuse Atrophy in Young Women

McMaster University20 enrolled

Overview

This study will examine the influence of n3 PUFA supplementation on the rate of muscle atrophy in women undergoing 2 weeks of unilateral limb immobilization. Assessments in skeletal muscle strength and skeletal muscle volume will also me made before, after and in recovery from immobilization.

Biological aging is associated with the loss of skeletal muscle mass and strength resulting in compromised metabolic function and mobility. Throughout life, individuals will also experience periods of reduced physical activity/muscle disuse that independently lower muscle mass and strength accelerating the aging process. The losses in muscle mass with aging and disuse are underpinned by feeding-induced declines in rates of muscle protein synthesis. Thus, strategies to enhance muscle protein synthesis could have clinical implications for those who wish to maintain metabolic health and function during times of muscle disuse. Supplementation with n3 PUFA-enriched fish oil has been shown to potentiate rates of muscle protein synthesis in response to simulated feeding in both younger and older adults. Fish oil supplementation also has been efficacious in enhancing skeletal muscle strength during a period of resistance exercise training. However, no study has examined the impact of fish oil supplementation to enhance muscle protein synthesis and offset declines in muscle mass/strength during a period of immobilization.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Muscle Atrophy

Interventions

n3 PUFA-enriched fish oilDIETARY_SUPPLEMENT

3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day

PlaceboDIETARY_SUPPLEMENT

Organic Sunflower Oil 5000mg per day

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 30 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Female * Aged 18-30 years Exclusion Criteria: * Take any analgesic or anti-inflammatory drugs(s), prescription or non-prescription, chronically will be excluded * A history of neuromuscular problems or muscle and/or bone wasting diseases * Any acute or chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin- or non-insulin dependent diabetes or other metabolic disorders-all ascertained through medical history screening questionnaires * Use medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications) * Fish allergy

Locations (1)

Exercise Metabolism Research Laboratory, McMaster Univeristy

Hamilton, Ontario, Canada

Outcomes

Primary Outcomes

Muscle Volume

Change in Muscle Volume Measured by Magnetic Resonance Imaging

Time frame: Baseline (0 days), After (14 days) of unilateral limb immobilization and at 14 days post immobilization

Secondary Outcomes

Integrated Rates of Muscle Protein Synthesis

Change in Muscle Protein Synthesis

Time frame: Before (0 days), During (0-14 days inclusive), and After (14-28 days inclusive) of unilateral limb immobilization

Skeletal Muscle Strength

Change in Skeletal Muscle Strength

Time frame: Before (0 days), After (14 days) of unilateral limb immobilization and at 14 days Post immobilization

Muscle Lipid Composition

Change in Muscle Lipid Composition

Time frame: Baseline (-28 days), and at Before (0 days), After (14 days) of unilateral limb immobilization and at 14 days Post immobilization

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.